As part of the contract, Abbott will supply analytical equipment and consumables, including the Alinity ci and Alinity h series diagnostics instruments.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
Alere is divesting Epocal as it seeks regulatory approval of its merger with Abbott. Based in Ottawa, Ontario, Epocal develops point-of-care blood diagnostic systems.
Abbott CEO Miles White said that he is confident that Abbott's acquisition of Alere will close as expected before the end of Q3.
The purchase of Alere's Series B convertible perpetual preferred stock at $402 per share is in connection to Abbott's $5.3 billion acquisition of Alere.
Quidel said that the purchases, expected to close in September, would give it an expanded portfolio of rapid diagnostic capabilities in critical care.
About 63 million votes were in favor of the deal, representing more than 72.5 percent of all outstanding Alere shares as of the May 31 record date.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
The analyzer, part of Abbott's Alinity portfolio, is designed to streamline clinical workflows for high-volume laboratories and hospital systems.